Tech Digest

Anti-Aging Biotechnologies Will Make Social Security and Medicare Obsolete

Stay Up to Date!

Simply enter your email below and click SIGN UP!

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

July 30, 2018

Dear Reader,

Because transfer payments to the aged now make up the biggest part of the federal budget, I continually hear from people who fear anti-aging therapeutics will make things worse.

LIMITED TIME OFFER
-
“Mauldin VIP has provided the best and most accurate information for understanding the past and anticipating the future out of all of the reading I do. Keep up the great work and the VIP program!!"
— Robert L.
Save at least 66% on Mauldin VIP now

Extending lives by another few years, they say, will only increase the amount of time that people are receiving transfer payments.

This isn't true. In fact, the opposite will happen.

Social Security and Medicare as we now know them will disappear because they won't be needed. I've covered this before, so I apologize for repeating myself.

Right now, biotechnologies that will dramatically extend human healthspans are moving toward the market. Some are already known to those who monitor biogerontology, but others have carefully avoided publicity. When these breakthrough therapies finally arrive, the economy will undergo the most dramatic transformation since the Industrial Revolution.

To understand the future economic impact of longer lifespans, we need at least some grasp of the effects longer lifespans have already had. 

The Biggest Change That Almost Nobody Noticed

The improvements in living standards and lifespans that came out of the scientific revolution and the Enlightenment were accompanied by falling birthrates. By the middle to the late 20th century, most developed nations' populations were no longer replacing themselves.

The following chart from the invaluable Our World in Data website provides a few visual examples.


Source: https://ourworldindata.org/grapher/birth-rate-the-number-of-births-per-1000-people-in-the-population?country=AUS+CHN+England%20and%20Wales+FRA+IND+JPN+RUS+ESP+OWID_GFR

As you can see, birthrates in the countries with data reaching back to the 1800s fell by at least two-thirds. At the same time, life expectancies basically doubled.

In retrospect, this is the biggest change in human history… so far. Ironically, almost nobody seemed to notice.

There were exceptions, of course. In the 1930s, a few demographers figured out what was going on and wrote about it in academic journals and texts. However, their influence was washed away by the overpopulation hysteria of the 1970s.

Nearly all our major intellectual institutions—including academia, the UN, and mainstream media—got it completely backwards, envisioning an inevitable overpopulation apocalypse and blaming it on high birthrates.

If first-world governments had only acknowledged that growing older populations depended on a shrinking tax base of younger people, we could have prepared. Instead, most of them borrowed money to fund programs for the aged, creating catastrophic levels of debt.

Today, international debt levels are nearly comparable to those created by World War II, but with no post-war baby boom to pay them off. As a result, the world is facing a financial and humanitarian catastrophe that could dwarf the Great Depression.

Why did this happen?

Obviously, political and psychological factors contributed to the situation—but I think the main reason is that it happened so slowly.

Most people simply didn’t notice as birthrates and life expectancies changed. A few demographers crunching the numbers knew, but their voices were lost in the blizzard of everchanging political and media panics. 


Source: https://fred.stlouisfed.org/series/SPDYNLE00INUSA

Since 1960, life expectancy in the United States has increased by about two months every year, but that wasn’t sufficient to penetrate public consciousness. We have not yet accepted that retirement models instituted when few workers lived to 70 are untenable today.

That will change, though. Discoveries made in just the last decade will enable much greater and much more rapid increases in lifespans.

I predict that within the next three to five years, we’ll see evidence that animal healthspans can be doubled at least. I’m also convinced several of the therapies that can do this will have a similar impact on humans.

If nothing changes on the legal front, it would mean that we are 10–15 years away from regulatory approval for human use of radical healthspan-extending therapies. However, the Japanese Ministry of Health, Labour and Welfare has implemented mechanisms for accelerating regenerative medicine that could reduce the delay to only a year or two. Other countries facing demographic catastrophes are also discussing major regulatory changes for anti-aging therapies.

Japanese approval wouldn’t allow use in the US, but health tourism would put these therapies within reach of wealthier Americans. In the case of radical regenerative medicine, that would be enough to force a real healthcare revolution.

The reason is that emerging regenerative therapies don’t just delay aging and death. I’ve recently written a lot about rapamycin, even though much more effective therapies are in the works. Rapamycin plays a critical role in this story because its use in animals shows that regenerative medicine leads to obvious rejuvenation. Aged mice treated with rapamycin regain hair, mobility, muscle mass, acuity, sexual vigor, and more.

When humans undergo even more effective therapies, their biomarkers will mimic those of younger people, but they’ll also appear, feel, and function as if they were younger. Public sentiment will shift dramatically when older celebrities visibly rejuvenate.

At that point, Millennials and other young people will truly understand just how unfair the current system is. Older people will also accept the responsibilities that come with much longer healthspans.

More importantly, the cost of healthcare will plummet because healthspans will be significantly extended. The diseases that enfeeble and kill will be delayed or prevented entirely. Social Security and Medicare, at least in their current forms, will be obsolete.

Before I go, let me quickly point out that the VIP membership offer is currently on the table, but only for a little over a week. When you combine all of Mauldin Economics’ services and allocate them just right for your personal needs, you should end up with a powerful portfolio.

Use the TransTech Alert for your high-stakes, long-term allocation and balance it out with Jared Dillian’s fund recommendations in ETF 20/20 or Robert Ross’s safe, income-generating picks in Yield Shark.

This is just an example, of course. There are endless ways to mix and match our strategies and stock picks. For some inspiration, read the special report How to Build Your VIP Portfolio that comes with your VIP membership.

What’s so great about VIP? Consider that you get all seven services we publish for a full year—for just $500 more than you would pay for a one-year subscription of TransTech Alert alone. (Which, of course, is included in your VIP membership.) Click here to learn more.

Sincerely,
Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics

 

Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest


Your privacy is very important to us. Please review our Privacy Policy.

Tags:

« Back to Articles

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

Discuss This

0 comments

We welcome your comments. Please comply with our Community Rules.

Comments

detlefschmitt@mac.com

Aug. 1, 8:04 a.m.

I am personally skeptical about the growth potential of Chromadex. First of all the stock has been trading since 2008 up and down between $1 and $6. So far there is no growth. And second, although Chromadex has an exclusive license for the manufacturing process, I believe that, in the case that this nutritional supplement will draw exceptional sales, that the large players in the Vitamine field will circumvent the Chromadex license with an alternative production process and with their sales power capture the majority of the market leaving little room for growth for Chromadex. In addition, while this Vitamine B3 precursor promises to have some benefits e.g. on blood pressure and vascular stiffness, it may not have other benefits for normally aging people making making it just another ordinary supplement like Vitamine C or D. One has to be careful about the hyb that is been created around aging related drugs and supplements. Some of it could turn out to be snake oil, in the worst case.

For those interested in more information I recommend the below articles.

1. Chronic nicotinamide ribosome supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876407/)
2. NAD metabolism: Implications in aging and longevity (https://www.sciencedirect.com/science/article/pii/S1568163718300060)
3. The business of anti-aging science (https://www.sciencedirect.com/science/article/pii/S0167779917301713)
4. What is aging? PhD Comics Animation (video) (http://pcwww.liv.ac.uk/~aging/)

detlefschmitt@mac.com

July 31, 8:31 a.m.

I have been working in drug development for over 30 years in research as a biomedical scientist. I have also extensively studied biotech companies listed on the NASDAQ and the AMEX. I was especially interested in the characteristics that make a biotech successful versus a failure. My conclusion is that the growth of the biotech sector is basically driven by technology platforms that could be leveraged to target many diseases. The first one was the antibody technology. These companies are now mature. The next revolution, which is now entering the market with its first drugs is antisense/siRNA. Another one emerging is mRNA drugs. After that, it could be CRISPR. But CRISPR is still very immature and could take another 10 years for first market entries. In contrast to those breakthrough technologies that have driven and will drive biotech sector growth are a large number of one drug companies of which most have and will in the future end on the biotech graveyard.

Inspired by Patrick I had a look at the biotech companies involved in developing drugs and food additives to treat aging. As a whole, these companies strike me as one drug like companies. I can therefore only suggest to spread your money and invest in many of them because it is difficult to tell which one will make it.

Aging is a process that involves many different intracellular mechanisms. Many of them are currently under investigation in animal models. Some look very promising. But one has to be very careful extrapolating positive results from animals to humans. Even if one can extend the life of a mouse 10 fold that may not result in any meaningful gains in humans. Another problem in this field is that clinical trial will be long unless suitable biomarkers and clinical endpoints have been identified and accepted by FDA. There will not be a quick path to market unless it is a food additive.

Nevertheless, the aging field is an emerging field that promises high growth rates, but it is difficult to cherry pick. For that reason, I am not willing to invest in this field now.

cparks_y@yahoo.com

July 30, 1:04 p.m.

You essay ignores the fact that there is a large enough contingent of voters who elected a president who believes Coal Mining is a career. Another group that believes current technology is evil, wont use e-banking, avoid GMO related products, etc. An last the group that believes vaccines are the cause of developmental issues. I hope you’re right but US resistance to change is a very powerful opponent of rational thinking.

lane.ginsberg@gmail.com

July 30, 12:40 p.m.

OK, so Medicare as we know it becomes obsolete over time. Social Security obsolete?  Has there ever been a time when the need for income vanished?  I don’t think so. Are the current Boomers supposed to work until 85?  I may, but then I own my own business and it doesn’t necessitate heavy physical labor. I don’t think Boomers are up to it. The average retirement is still 64 for a guy, and 62 for a gal. I’ve got clients who want to retire at 60 after 35 years of hard labor!

Unused Medicare funds, if any, could go to reduce the national debt, but most likely they will be spent frivolously by our elected representatives.

The longer people live the more likely they are to outlive their money, healthy or not. That is the challenge. 


Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact service@mauldineconomics.com.

Disclaimers

The Mauldin Economics website, Thoughts from the Frontline, The Weekly Profit, The 10th Man, Connecting the Dots, Transformational Technology Digest, Over My Shoulder, Yield Shark, Transformational Technology Alert, Rational Bear, Street Freak, ETF 20/20, In the Money, and Mauldin Economics VIP are published by Mauldin Economics, LLC Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to http://affiliates.ggcpublishing.com/. Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2018 Mauldin Economics